Analysts expect Jupiter Neurosciences, Inc. to report revenue of 0.00 for Q3 25, against a range of 0.00 to 0.00. The most recent reported quarter, Q2 25, came in at 0.00.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | 0.00 | 0.00 | 0.00 | 0.00 | - | - | - | - | - | - | - | - | ||||||
| High Estimate | - | 0.00 | 0.00 | 0.00 | 0.00 | 75,728.94 | 238,619.36 | 439,220.27 | 602,172.02 | 12.17 M | 1.31 M | 1.65 M | ||||||
| Low Estimate | - | 0.00 | 0.00 | 0.00 | 0.00 | 64,211.30 | 221,082.64 | 405,107.73 | 557,346.20 | 10.13 M | 1.18 M | 1.52 M | ||||||
| Consensus Estimate | - | 0.00 | 0.00 | 0.00 | 0.00 | 69,970.12 | 229,851.00 | 422,164.00 | 579,759.11 | 11.15 M | 1.24 M | 1.59 M |
Analysts expect Jupiter Neurosciences, Inc. to report earnings per share of -6.35 for Q3 25, against a range of -6.83 to -5.87. The most recent reported quarter, Q2 25, came in at -5.25, a 4.2% miss against the -5.04 consensus.
| Metric | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | Q3 26 | Q4 26 | Q1 27 | Q2 27 | Q3 27 | Q4 27 | Q1 28 | Q2 28 | Q3 28 | Q4 28 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Reported (Actual) | -1.50 | -3.75 | -3.75 | -5.25 | - | - | - | - | - | - | - | - | ||||||
| High Estimate | - | -1.33 | -3.74 | -4.70 | -5.87 | -5.18 | -3.83 | -3.63 | -3.40 | 14.07 | -3.66 | -4.51 | ||||||
| Low Estimate | - | -1.49 | -4.18 | -5.38 | -6.83 | -5.60 | -4.07 | -4.07 | -3.88 | 13.15 | -4.12 | -5.37 | ||||||
| Consensus Estimate | - | -1.41 | -3.96 | -5.04 | -6.35 | -5.39 | -3.95 | -3.85 | -3.64 | 13.61 | -3.89 | -4.94 |